EPCR缺失或功能阻断抗体可预防血友病小鼠关节出血诱导的病理改变
本研究在血友病A(FVIII-/-)小鼠中构建EPCR缺失或过表达模型,通过针刺诱导关节出血,评估血友病性滑膜炎。结果显示EPCR缺失显著减轻滑膜炎严重程度,减少IL-6、巨噬细胞浸润和新生血管形成;单次rFVIIa即可完全预防EPCR-/-FVIII-/-小鼠的轻度滑膜炎;EPCR阻断单抗同样显著减轻滑膜炎。提示EPCR是预防血友病患者关节损伤的新靶点。
要点
- EPCR缺失减轻血友病小鼠关节出血后的滑膜炎及炎症、血管新生。
- 单次rFVIIa可完全预防EPCR缺失小鼠的轻度血友病性滑膜炎。
- EPCR阻断单抗显著减轻血友病小鼠关节出血后的滑膜炎。
核心结论
- EPCR缺失或功能阻断可保护血友病小鼠免受关节出血诱导的滑膜炎和关节病理。
- EPCR可能是预防血友病患者关节损伤的新靶点。
研究设计与样本
- 生成EPCR缺失(EPCR-/-FVIII-/-)或EPCR过表达(EPCR++FVIII-/-)的血友病A(FVIII-/-)小鼠。
- 通过针刺损伤诱导FVIII-/-、EPCR-/-FVIII-/-和EPCR++FVIII-/-小鼠关节出血。
- 通过监测关节出血、关节直径变化及关节组织切片组织病理学分析评估血友病性滑膜炎。
主要发现
- EPCR缺失显著降低FVIII-/-小鼠血友病性滑膜炎的严重程度。
- EPCR缺失减弱关节出血后滑膜中白细胞介素-6的生成、巨噬细胞浸润和新生血管形成。
- 单次剂量rFVIIa足以完全预防EPCR-/-FVIII-/-小鼠较轻血友病性滑膜炎的发生。
- EPCR过表达FVIII-/-小鼠的血友病性关节病发展与FVIII-/-小鼠无显著差异,3次剂量rFVIIa部分保护其滑膜炎。
- 单次剂量EPCR阻断单克隆抗体显著减轻关节出血FVIII-/-小鼠的血友病性滑膜炎。
临床怎么用
- EPCR可能成为预防血友病患者关节损伤的新治疗靶点。
- EPCR阻断抗体或rFVIIa在临床前模型中显示保护作用,尚需进一步转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We recently showed that clotting factor VIIa (FVIIa) binding to endothelial cell protein C receptor (EPCR) induces anti-inflammatory signaling and protects vascular barrier integrity. Inflammation and vascular permeability are thought to be major contributors to the development of hemophilic arthropathy following hemarthrosis. The present study was designed to investigate the potential influence of FVIIa interaction with EPCR in the pathogenesis of hemophilic arthropathy and its treatment with recombinant FVIIa (rFVIIa). For this, we first generated hemophilia A (FVIII-/-) mice lacking EPCR (EPCR-/-FVIII-/-) or overexpressing EPCR (EPCR++ FVIII-/-). Joint bleeding was induced in FVIII-/-, EPCR-/-FVIII-/-, and EPCR++FVIII-/- mice by needle puncture injury. Hemophilic synovitis was evaluated by monitoring joint bleeding, change in joint diameter, and histopathological analysis of joint tissue sections. EPCR deficiency in FVIII-/- mice significantly reduced the severity of hemophilic synovitis. EPCR deficiency attenuated the elaboration of interleukin-6, infiltration of macrophages, and neoangiogenesis in the synovium following hemarthrosis. A single dose of rFVIIa was sufficient to fully prevent the development of milder hemophilic synovitis in EPCR-/-FVIII-/- mice. The development of hemophilic arthropathy in EPCR-overexpressing FVIII-/- mice did not significantly differ from that of FVIII-/- mice, and 3 doses of rFVIIa partly protected against hemophilic synovitis in these mice. Consistent with the data that EPCR deficiency protects against developing hemophilic arthropathy, administration of a single dose of EPCR-blocking monoclonal antibodies markedly reduced hemophilic synovitis in FVIII-/- mice subjected to joint bleeding. The present data indicate that EPCR could be an attractive new target to prevent joint damage in hemophilia patients.
引用
- Magisetty J, Pendurthi UR, Esmon CT, et al. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice. Blood. 2020. PMID: 32294155. doi:10.1182/blood.2019003824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。